Large hemispheric infarction (LHI) is a distinct form of arterial ischemic stroke characterized by marked tissue swelling that is often associated with herniation, death, or poor neurological outcome.1,2 Cerebral edema that occurs within the rigid cranial vault increases intracranial pressure, causing additional brain damage, and in many instances, herniation and death. Current medical therapies for acute stroke and edema include head-of-bed elevation, osmotic therapy, sedation, and supportive care, but clinical trial evidence for these strategies is limited.2,4 In LHI, outcomes in patients ≤60 years of age may be improved with decompressive craniectomy—an invasive procedure with nontrivial complications.5

Background and Purpose—We aimed to determine whether subjects aged ≤70 years who were treated with intravenous glyburide (RP-1127; BIIB093; glibenclamide) would have better long-term outcomes than those who received placebo.

Methods—GAMES-RP (Glyburide Advantage in Malignant Edema and Stroke–Remedy Pharmaceuticals) was a prospective, double-blind, randomized, placebo-controlled phase 2 clinical trial. Eighty-six participants, aged 18 to 80 years, who presented to 18 centers with large hemispheric infarction (baseline diffusion-weighted imaging volumes, 82–300 cm³) randomized within 10 hours of symptom onset were enrolled. In the current exploratory analysis, we included participants aged ≤70 years treated with intravenous glyburide (n=35) or placebo (n=30) who met per-protocol criteria. Intravenous glyburide or placebo was administered in a 1:1 ratio. We analyzed 90-day and 12-month mortality, functional outcome (modified Rankin Scale, Barthel Index), and quality of life (EuroQol group 5-dimension). Additional outcomes assessed included blood–brain barrier injury (MMP-9 [matrix metalloproteinase 9]) and cerebral edema (brain midline shift).

Results—Participants ≤70 years of age treated with intravenous glyburide had lower mortality at all time points (log-rank survival hazards ratio, 0.34; P=0.04). After adjustment for age, the difference in functional outcome (modified Rankin Scale) demonstrated a trend toward benefit for intravenous glyburide-treated subjects at 90 days (odds ratio, 2.31; P=0.07). Repeated measures analysis at 90 days, 6 months, and 12 months using generalized estimating equations showed a significant treatment effect of intravenous glyburide on the Barthel Index (P=0.03) and EuroQol group 5-dimension (P=0.05). Participants treated with intravenous glyburide had lower plasma levels of MMP-9 (189 versus 376 ng/mL; P<0.001) and decreased midline shift (4.7 versus 9 mm; P<0.001) compared with participants who received placebo.

Conclusions—In this exploratory analysis, participants ≤70 years of age with large hemispheric infarction have improved survival after acute therapy with intravenous glyburide.

Key Words: brain edema ■ glyburide ■ infarction ■ ischemic stroke ■ malignant infarction

Received December 5, 2017; final revision received April 11, 2018; accepted April 17, 2018.

From the Division of Neurocritical Care and Emergency Neurology, Department of Neurology (K.N.S., N.H.P.) and Department of Radiology (G.K.S.), Yale University School of Medicine, New Haven, CT; Department of Biostatistics, Columbia University, New York, NY (K.C.C.); Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E.); Department of Neurology, Oregon Health Sciences University, Portland (H.E.H.); Department of Neurology, University of Pittsburgh, PA (B.J.M.); Division of Neurology, Children’s Hospital of Philadelphia, Departments of Neurology and Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (L.A.B.); Department of Neurosurgery, University of Maryland School of Medicine, Baltimore (J.M.S.); and Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Massachusetts General Hospital, Boston (W.T.K.).

*Drs Sheth and Petersen contributed equally.


Correspondence to Kevin N. Sheth, MD, Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale University School of Medicine, 15 York St, LCI 1003, New Haven, CT 06510, E-mail kevin.sheth@yale.edu or W. Taylor Kimberly, MD, PhD, Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Massachusetts General Hospital, Lunder 644, 55 Fruit St, Boston, MA 02114, E-mail wtkimberly@partners.org

© 2018 American Heart Association, Inc.

Stroke is available at http://stroke.ahajournals.org

DOI: 10.1161/STROKEAHA.117.020365
Emerging studies have implicated the sulfonylurea receptor 1–transient receptor potential melastatin 4 channel as a mediator of edema formation and as a potential therapeutic target. Channel blockade in multiple preclinical models of stroke has demonstrated edema reduction and improved survival and neurological outcome. Ongoing efforts are evaluating whether this pathway may be a suitable therapeutic target in human stroke.

Brain atrophy increases with age, particularly in individuals >70 years of age. Age-related cerebral atrophy in older patients may protect against space-occupying brain edema by providing room to compensate for the increase in volume. Several prior studies of LHI in adults have identified decreased age as a predictor of poor outcome. In addition, observational evidence suggests that patients >70 years of age have an increased frequency of withdrawal of care, especially in brain injuries where the initial insult is a major predictor of outcome. Therefore, subjects ≤70 years of age may be the most appropriate target population to test an intervention that reduces cerebral edema.

GAMES-RP (Gliburide Advantage in Malignant Edema and Stroke–Remedy Pharmaceuticals) was a randomized trial of intravenous gliburide versus placebo in patients aged 18 to 80 years at high risk for malignant cerebral edema, which found no difference in the primary outcome (composite outcome of decompressive craniectomy and functional outcome). However, there was decreased midline shift (MLS) in intravenous gliburide-treated subjects, and the results suggested a potential survival benefit for patients treated with gliburide. Here, we report an exploratory analysis of GAMES-RP in subjects ≤70 years of age, in which we evaluated whether treatment with intravenous gliburide would reduce MLS and decrease mortality. In addition to assessing 90-day outcomes in these subjects, we also evaluated their mortality, functional outcomes, disability, and quality of life at 1 year.

Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.

Study Design and Subjects
GAMES-RP was a double-blind, randomized, placebo-controlled phase 2 trial of intravenous gliburide in subjects with anterior circulation LHI (baseline diffusion-weighted imaging volume of 82–300 cm³). The study enrolled patients aged 18 to 80 years from 18 centers in the United States who received study drug or placebo within 10 hours of symptom onset. The study methods and patient eligibility criteria have been reported. The study was approved by the institutional review boards at all participating centers. All participants or their legally authorized representatives provided written informed consent at enrollment. In this subgroup analysis, we included only subjects who were ≤70 years of age and who met per-protocol criteria. Key per-protocol criteria included administration of study drug or placebo and core laboratory verification of baseline infarction volume within the prespecified range (82–300 cm³).

Outcome Measurements
In the current subgroup analysis, we evaluated (1) functional outcome, measured with the modified Rankin Scale (mRS) including mortality, (2) activities of daily living, measured by the Barthel Index, and (3) health-related quality of life, evaluated with the EuroQol group 5-dimension (EQ-5D). Outcomes were assessed at 90 days, 6 months, and 12 months. The EQ-5D utility score measures 5 domains of general health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and integrates the ratings into a single score, calculated using population-based preference weights for each subscale. In the present analysis, we used the weights obtained from the US population. Utility scores express health-related quality of life quantitatively as a fraction of perfect health, with a score of 1 representing perfect health and a score of 0 representing death. Outcomes were assessed either in person or by telephone by qualified raters blinded to treatment allocation. Additional outcomes included MLS and plasma concentration of MMP-9 (matrix metalloproteinase 9). MLS was measured by the blinded central imaging core on the day-4 magnetic resonance imaging. The midline was defined as the anatomic line anchored by the falx cerebri to the skull. MLS was drawn perpendicular at the point of maximum distention, at the level of the septum pellucidum. Total MMP-9 plasma concentration during study drug infusion at 24 to 72 hours (mean level of 3 daily samples) was measured with a commercially available assay (Human MMP-9 Quantikine ELISA; R&D Systems, Minneapolis, MN).

Statistical Analyses
All analyses were performed on the per-protocol sample, which included participants who had a centrally read DWI baseline lesion volume between 82 and 300 cm³ and who received any amount of the study drug or placebo. R (version 3.1.2) was used for all statistical analyses. Categorical variables were compared using Fisher exact test. Normally distributed continuous variables were summarized using means and SDs and were compared with t tests and 95% confidence intervals (CIs) for the mean. Non-normally distributed variables were summarized with medians and interquartile ranges, and distributions were compared using Mann–Whitney U tests. Shift analysis of the raw mRS scores at 90 days and 12 months was compared using the Mann–Whitney U test; effect sizes of the shift (common odds ratio [COR] and its 95% CI) were estimated using ordinal logistic regression. Multivariable analysis using generalized estimating equations with unstructured correlation matrix and robust jackknife variance estimate was used to evaluate the effect of intravenous gliburide on longitudinal clinical outcomes (Barthel Index, EQ-5D) at 90 days, 6 months, and 12 months. Missing values because of death on the Barthel Index were imputed using the worst score for each group. For subjects lost to follow-up or missing a 12-month mRS, the last observed mRS value (90 days or 6 months) was carried forward. Kaplan–Meier methods were used to estimate survival. A Cox proportional hazards model compared survival between those who received study drug versus placebo. The ordinal logistic regression, generalized estimating equations, and Cox regression were adjusted for age (≤60 versus 61–70 years) to account for any potential imbalance in this major prognostic variable. All P values are reported as 2 sided. Because of the exploratory nature of this analysis, statistical significance was set at 0.05, unadjusted for multiple comparisons. A statistical trend was noted if the P value was between 0.05 and 0.10.

Results

Subject Characteristics
Of the 86 subjects randomized in GAMES-RP, 77 were included in the per-protocol analysis. Of these, 65 subjects were ≤70 years of age; 35 of these subjects were randomly allocated to intravenous gliburide and 30 to placebo. For this subgroup, the mean age was lower in the intravenous gliburide group when compared with placebo (55±9 versus 60±7 years; P=0.02, t test). We performed an age-by-treatment interaction analysis for functional outcome (P=0.19), and indeed, in the age 71 to 80 group, the COR point estimate was 0.67 (favoring placebo) but was 2.49 in the <70 group. None of the other baseline characteristics differed significantly between the 2 treatment groups.
Two subjects were lost to follow-up after 90 days. There was no significant difference in the use of decompressive craniectomy between the 2 groups (37% in intravenous glyburide group versus 27% in placebo group; \( P = 0.43 \)).

Mortality, MLS, and MMP-9 Levels

All-cause mortality at 1 year was 5/35 (14%) in the intravenous glyburide group and 12/30 (40%) in the placebo group. The Kaplan–Meier curve presented in Figure 1 demonstrates that more deaths occurred in the placebo group within 30 days and that this group difference was sustained throughout the 12-month follow-up period. After adjusting for age, the hazard ratio was 0.34 (95% CI, 0.12–0.96; \( P = 0.04 \); Figure 1). The median MLS at the level of the septum pellucidum at 72 to 96 hours was 4.7 mm in the intravenous glyburide group versus 9.0 mm in the placebo group (\( P = 0.001 \); \( t \) test). Patients treated with intravenous glyburide had significantly lower concentrations of total MMP-9 compared with those treated with placebo (mean, 189 versus 367 ng/mL; \( P = 0.001 \); \( t \) test).

Functional Outcomes

In an unadjusted analysis, functional outcome at 90 days was better among subjects who received intravenous glyburide compared with those who received placebo (COR, 2.49; 95% CI, 1.02–6; \( P = 0.05 \); Figure 2). There was a slight reduction in the effect size during 12 months (COR, 2.24; 95% CI, 0.92–5.46; \( P = 0.08 \)). Although not statistically significant after adjusting for age group, the shift in the mRS still favored intravenous glyburide at 90 days (adjusted COR, 2.31; 95% CI, 0.93–5.72; \( P = 0.07 \)) and 12 months (adjusted COR, 2.11; 95% CI, 0.86–5.18; \( P = 0.10 \)).

An additional analysis among participants who did not undergo decompressive craniectomy showed a point estimate of the COR was 2.84 (\( P \) value of 0.063).

Subjects treated with intravenous glyburide had higher scores on the Barthel Index and EQ-5D at all time points when compared with patients who received placebo (Table 2). Repeated measures analysis at 90 days, 6 months, and 12 months showed a significant treatment effect of intravenous glyburide on Barthel Index (95% CI, 2.1–37; \( P = 0.03 \)) and EQ-5D (95% CI, 0.001–0.249; \( P = 0.05 \)) after adjusting for age. Because of the possibility that long-term outcomes were driven by an early difference in mortality between groups, we performed an additional analysis on survivors, which did not show a difference between groups (Table 3). Figure 3 illustrates the time trend in treatment effect for both outcome variables (Barthel Index and EQ-5D).

**Table 1. Demographics and Baseline Characteristics in GAMES-RP Subjects Aged \( \leq 70 \) Years**

<table>
<thead>
<tr>
<th>Demographics</th>
<th>IV Glyburide (n=35)</th>
<th>Placebo (n=30)</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y (SD)</td>
<td>55 (9)</td>
<td>60 (7)</td>
<td>0.017</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>2 (6%)</td>
<td>3 (10%)</td>
<td>0.65</td>
</tr>
<tr>
<td>Non-Hispanic</td>
<td>33 (94%)</td>
<td>27 (90%)</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>30 (86%)</td>
<td>26 (87%)</td>
<td>1</td>
</tr>
<tr>
<td>Black</td>
<td>3 (9%)</td>
<td>2 (7%)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>2 (6%)</td>
<td>2 (7%)</td>
<td></td>
</tr>
<tr>
<td>Stroke characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cause of stroke</td>
<td></td>
<td></td>
<td>0.11</td>
</tr>
<tr>
<td>Large artery atherosclerosis</td>
<td>10 (29%)</td>
<td>7 (23%)</td>
<td></td>
</tr>
<tr>
<td>Cardioaortic embolism</td>
<td>11 (31%)</td>
<td>16 (53%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>3 (9%)</td>
<td>4 (13%)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>11 (31%)</td>
<td>3 (10%)</td>
<td></td>
</tr>
<tr>
<td>Internal carotid artery occlusion</td>
<td>12 (34%)</td>
<td>11 (37%)</td>
<td>1</td>
</tr>
<tr>
<td>Left-sided infarction</td>
<td>18 (51%)</td>
<td>17 (57%)</td>
<td>0.80</td>
</tr>
<tr>
<td>Baseline NIHSS score</td>
<td>19 (16–22)</td>
<td>21 (16–23)</td>
<td>0.24</td>
</tr>
<tr>
<td>Baseline DWI, cm(^2)</td>
<td>164 (52)</td>
<td>167 (50)</td>
<td>0.83</td>
</tr>
<tr>
<td>Baseline blood glucose, mg/dL</td>
<td>120 (104–156)</td>
<td>123 (108–139)</td>
<td>1</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intravenous rtPA</td>
<td>21 (60%)</td>
<td>19 (63%)</td>
<td>0.80</td>
</tr>
<tr>
<td>Time intervals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to rtPA, h</td>
<td>2.1 (1.0)</td>
<td>2.3 (1.1)</td>
<td>0.63</td>
</tr>
<tr>
<td>Time to MRI, h</td>
<td>6.0 (1.7)</td>
<td>5.8 (1.7)</td>
<td>0.72</td>
</tr>
<tr>
<td>Time to study drug, h</td>
<td>8.7 (1.3)</td>
<td>9.0 (1.3)</td>
<td>0.35</td>
</tr>
</tbody>
</table>

Data are mean (SD), mean (range), n (%), and median (IQR). DWI indicates diffusion-weighted imaging; GAMES-RP, Glyburide Advantage in Malignant Edema and Stroke–Remedy Pharmaceuticals; IQR, interquartile range; IV, intravenous; MRI, magnetic resonance imaging; NIHSS, National Institutes of Health Stroke Scale; and rtPA, alteplase.

**Discussion**

We present the results of an exploratory analysis of 12-month outcomes in subjects from the GAMES-RP study who were aged \( \leq 70 \) years. Though the age–treatment interaction did not reach significance (\( P = 0.19 \)), participants in the subgroup who received intravenous glyburide had improved survival compared with those who received placebo. Although the primary efficacy analysis from GAMES-RP\(^6\) did not meet the prespecified efficacy end point, these data suggest that patients \( \leq 70 \) years of age, who may be at higher risk of adverse clinical outcomes from cerebral edema, may benefit from therapy that inhibits edema formation.

The basis for the selection of age 70 as the cut point for this analysis rests on a biological and clinical premise directly relevant to edema prevention trials. In large, prospective, population-based cohorts, brain atrophy is known to increase above the age of 70 years.\(^2\) Moreover, longitudinal studies using high-resolution magnetic resonance imaging have demonstrated an age-related decrease in total brain volume that seems to accelerate after 70 years of age.\(^26–28\) In patients with LHI, decreasing age is also a known predictor of the inability to tolerate the consequences of swelling.\(^29\) Furthermore,
Lee et al demonstrated that cerebral atrophy above a certain threshold (intercaudate distance, >20 mm) had an independent protective effect against brain herniation and the need for decompressive craniectomy, while simultaneously predicting poor functional outcome. In addition, a recent study by Goto et al showed that elderly subjects with LHI required significantly larger infarct volumes to develop malignant edema and decreased level of consciousness when compared with subjects with lower age. Inclusion of brain atrophy as a marker of protective effect, in addition to the use of lesion volume as a prognostic factor, has led to more accurate prediction of a malignant course after LHI. We measured baseline hemisphere volume in GAMES-RP, and the median hemisphere volume in subjects >70 years of age was lower compared with subjects aged ≤70 years (492 versus 546 cm³; P=0.003).

Clinically, withdrawal of care is often the predominant mechanism of death in patients >70 years of age with acute brain injury. In patients with severe brain injury (eg, cardiac arrest or LHI), in which the severity of the initial insult is a strong predictor of outcome, withdrawal of care is especially common >70 years of age. Withdrawal of care is often because of disability related to the initial infarction or potentially undesirable procedures, such as placement of feeding tube or tracheostomy. Given the more prominent effects of cerebral edema in subjects ≤70 years of age, future investigations of efficacy of intravenous glyburide should focus on this population.

In GAMES-RP, we included established instruments to evaluate multiple dimensions of outcome after LHI. LHI is among the most devastating forms of arterial ischemic stroke with mortality rates as high as 50%. Although decompressive craniectomy has been shown to reduce death and, in selected subjects, improve outcomes, survivors often have severe disability and functional dependence. In addition to impaired motor function, these patients frequently experience injury to other domains, including cognition, language, and visual function, all of which significantly contribute to their overall outcomes. Many physicians, therefore, have concerns about the long-term quality of life among survivors of LHI. Conversely, patients frequently achieve a satisfying level of psychological well being, despite their severe physical deficits. Furthermore, van Middelaar et al showed that patients who underwent surgical decompression for space-occupying middle cerebral artery infarction have a good mental quality of life that is comparable with the general population, and the majority of patients and caregivers would, in retrospect, again opt for surgery. We applied the EQ-5D and Barthel Index to

**Figure 1.** Kaplan–Meier survival curve for each treatment group.

**Figure 2.** Functional outcomes on modified Rankin Scale (mRS) at 90 days (A) and 12 months (B) in subjects aged ≤70 years.
assess 12-month quality of life and to explore whether or not patients with moderately severe disability have acceptable outcomes. The significant difference in the EQ-5D and Barthel Index observed in the present analysis suggests that these instruments provide additional important insights into overall quality of life after LHI, which is particularly important in the subgroup of patients with moderate-to-severe disability. However, after excluding patients who died, the treatment effect was no longer significant (Table 3)—a finding that suggests the difference in Barthel Index and EQ-5D in this subgroup of patients with moderate-to-severe disability. Therefore, be included in future investigations of efficacy to assess whether treatment with intravenous glyburide can, in addition to reducing mortality, lead to meaningful improvements in quality of life.

After the initial 90 days, we observed continued improvement ≤6 months, with moderate relative gains in recovery in both groups. Subsequently, outcomes remained stable to 12 months (Figure 3). These findings suggest that outcome at 90 days may inform longer term outcome and likely constitutes a meaningful end point for future studies of intravenous glyburide.

In this subgroup of patients ≤70 years of age, treatment with intravenous glyburide led to a 51% reduction in plasma MMP-9 levels, which is greater than the 39% reduction seen in the overall GAMES-RP cohort. MMP-9 is a marker of blood–brain barrier disruption and has been associated with cerebral edema after stroke.³⁹ MLS is another marker for cerebral edema after LHI. The extent of lateral displacement of midline structures has been correlated with decreased level of consciousness—a finding that was also seen in GAMES-RP.⁵ The significant reduction in MLS in patients treated with intravenous glyburide further supports the potential positive effect of this therapy on cerebral edema in patients ≤70 years of age.

A notable strength of our study is prospective data collection using standardized methods that address multiple domains, all at multiple time points. However, our study has important limitations. First, this study was an exploratory, post hoc subgroup analysis of the GAMES-RP trial. A significant imbalance in age could have favored the intravenous glyburide group. The small sample that results from any age cut point limits the power of analysis of the GAMES-RP trial. A significant imbalance in age could have favored the intravenous glyburide group. Alternatively, as a postmortem data analysis variable, it is also possible that decompressive craniectomy was performed in an inconsistent manner, favoring those patients most likely to benefit. Whereas decompressive craniectomy may improve outcome, craniectomy plus subsequent cranioplasty necessitates recovery from 2 surgeries, both of which expose patients to complications that can negatively impact outcome.

Clinical studies designed to detect an effect of a treatment that inhibits edema formation may consider enriching the population with patients ≤70 years of age. Although the present analyses are exploratory, the 12-month effects of glyburide on mortality provide evidence for a potential role in improving outcomes in patients with large hemispheric stroke. The results support additional study and prospective

### Table 2. Patient Outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Placebo (n=30)</th>
<th>IV Glyburide (n=35)</th>
<th>Effect Size (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d</td>
<td>10 (33%)</td>
<td>4 (11%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 mo</td>
<td>11 (37%)</td>
<td>5 (14%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 mo</td>
<td>12 (40%)</td>
<td>5 (14%)</td>
<td>HR, 0.34 (0.12–0.96)</td>
<td>0.042*</td>
</tr>
<tr>
<td>Barthel Index, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d</td>
<td>34.5 (36.5)</td>
<td>50.7 (36.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 mo</td>
<td>39.5 (39.3)</td>
<td>54.4 (37.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 mo</td>
<td>39.5 (40.1)</td>
<td>60.1 (37.9)</td>
<td>20 (2.1–37)</td>
<td>0.029†</td>
</tr>
<tr>
<td>EQ-5D, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d</td>
<td>0.29 (0.30)</td>
<td>0.43 (0.32)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 mo</td>
<td>0.33 (0.34)</td>
<td>0.49 (0.32)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 mo</td>
<td>0.33 (0.32)</td>
<td>0.49 (0.31)</td>
<td>0.154 (0.001–0.249)</td>
<td>0.048†</td>
</tr>
</tbody>
</table>

Data are n (%) and mean (SD). CI indicates confidence interval; IV, intravenous.

*P value is from a log-rank test.
†P value is from a linear, repeated measures GEE model for longitudinal outcomes.

### Table 3. Barthel Index for Survivors (After Exclusion of Subjects Who Had Died)

<table>
<thead>
<tr>
<th>Interval</th>
<th>Placebo</th>
<th>IV Glyburide</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barthel Index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>90 d</td>
<td>20</td>
<td>31</td>
<td>0.57*</td>
</tr>
<tr>
<td>6 mo</td>
<td>18</td>
<td>30</td>
<td>0.82*</td>
</tr>
<tr>
<td>12 mo</td>
<td>17</td>
<td>29</td>
<td>0.87*</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>Effect size (95% CI): IV glyburide-placebo</td>
<td>4.1 (−13 to 22)</td>
<td>0.64</td>
</tr>
<tr>
<td>12 mo</td>
<td>0.024 (−0.12 to 0.16)</td>
<td>0.74†</td>
<td></td>
</tr>
</tbody>
</table>

EQ-5D for survivors (after exclusion of subjects who had died). Imputation with 0 for death has not been applied. CI indicates confidence interval; IV, intravenous. Clinical studies designed to detect an effect of a treatment that inhibits edema formation may consider enriching the population with patients ≤70 years of age.

A notable strength of our study is prospective data collection using standardized methods that address multiple domains, all at multiple time points. However, our study has important limitations. First, this study was an exploratory, post hoc subgroup analysis of the GAMES-RP trial. A significant imbalance in age could have favored the intravenous glyburide group. The small sample that results from any age cut point limits the power of analysis of the GAMES-RP trial. A significant imbalance in age could have favored the intravenous glyburide group. Alternatively, as a postmortem data analysis variable, it is also possible that decompressive craniectomy was performed in an inconsistent manner, favoring those patients most likely to benefit. Whereas decompressive craniectomy may improve outcome, craniectomy plus subsequent cranioplasty necessitates recovery from 2 surgeries, both of which expose patients to complications that can negatively impact outcome.
trials designed to assess the role of intravenous glyburide, or BIIB093, for improving outcomes for patients with LHI.

Acknowledgments
Biogen was provided the ability to review this article. The authors maintained full control of all content.

Sources of Funding
Remedy Pharmaceuticals provided funding for GAMES-RP (Glyburide Advantage in Malignant Edema and Stroke—Remedy Pharmaceuticals). Dr Simard is supported by grants from the National Institutes of Health (R01 HL082517 and R01 NS060801).

Disclosures
Dr Simard has a patent related to the study and has shares in Remedy Pharmaceuticals. Drs Kimberly, Sheth, Elm, and Sze and Laboratory received grants from Remedy Pharmaceuticals during the conduct of this study. Drs Sheth and Kimberly also receive research grants from the American Heart Association. Drs Molyneaux and Hinson received grants from Remedy Pharmaceuticals outside of the submitted work.

Dr Elm received personal fees from Remedy. Dr Cheung received fees from Remedy. The other authors report no conflicts.

References
Long-Term Outcomes in Patients Aged ≤70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis


*Stroke.* 2018;49:1457-1463; originally published online May 22, 2018; doi: 10.1161/STROKEAHA.117.020365

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2018 American Heart Association, Inc. All rights reserved.

Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://stroke.ahajournals.org/content/49/6/1457

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org/subscriptions/